TITLE

Information about Summons to the Annual General Meeting of Diamyd Medical AB

PUB. DATE
November 2011
SOURCE
Biomedical Market Newsletter;11/16/2011, Vol. 21, p138
SOURCE TYPE
Periodical
DOC. TYPE
Proceeding
ABSTRACT
The article offers information on the Annual General Meeting of Diamyd Medical AB, to be held on December 7, 2011.
ACCESSION #
69589633

 

Related Articles

  • Diamyd Staves Off Liquidation, Returns Cash to Shareholders. Sheridan, Cormac // BioWorld International;2/20/2013, Vol. 18 Issue 8, p2 

    The article reports that Diamyd Medical AB has agreed to give back most of its cash to investors following pressure from rebel shareholders and will retain a small amount for the continuation of its two Phase II trials on glutamic acid decarboxylase (GAD) vaccine used in treating Type I...

  • Diamyd Climbs on $625M Type I Diabetes Deal.  // Bioworld Week;6/28/2010, Vol. 18 Issue 26, p4 

    The article reports on the deal to develop the Type I diabetes, entered by Diamyd Medical AB in Sweden.

  • Prevention Study with Diamyd's Diabetes Vaccine Fully Recruited.  // Biomedical Market Newsletter;1/14/2012, Vol. 21, p1 

    The article offers information on a study conducted by a research group at the Lund University in Sweden. A total of 50 children aged four- years and older with a high risk of developing type 1 diabetes have been enrolled DiAPREV-IT, a researcher-initiated Phase II study with diabetes vaccine...

  • Peter Zerhouni has been appointed Executive VP of Diamyd Medical AB.  // Biomedical Market Newsletter;5/7/2011, p160 

    The article announces the appointment of Peter Zerhouni as executive vice president of Diamyd Medical AB.

  • Diamyd Eyes Spring Start for Phase III Diabetes Trial. Sheridan, Cormac // BioWorld International;2/20/2008, Vol. 13 Issue 8, p2 

    The article reports on the plan by Stockholm, Sweden-based Diamyd Medical AB to begin a Phase III clinical trial of its therapeutic vaccine for Type I diabetes in spring. The U.S. Food and Drug Administration (FDA) questioned a minor aspect of the vaccine's manufacturing process. According to...

  • ADA 2011.  // BioWorld Today;6/29/2011, Vol. 22 Issue 125, p9 

    The article focuses on results presented by Diamyd Medical AB at the 2011 American Diabetes Association meeting from a European trial of its diabetes immunotherapy Diamyd.

  • Diamyd Medical: Quarterly Report II 10/11.  // Biomedical Market Newsletter;5/14/2011, p165 

    The article offers information on the quarterly report II of the company, Diamyd Medical AB for the year 2011 in the U.S. It mentions that the interest of the company is high and the company has more than 6,000 shareholders. It states that the company focuses on the development of...

  • Diamyd Medical: Diamyd Appoints Peter Zerhouni as President.  // Biomedical Market Newsletter;7/5/2011, p11 

    The article announces the appointment of Peter Zerhouni as president of Diamyd Medical AB.

  • DIAMYD MEDICAL LICENSES NOVEL PAIN PRODUCT.  // Worldwide Biotech;May2009, Vol. 21 Issue 5, p1 

    This article reports on the acquisition of an exclusive license for Endomorphin technology by Diamyd Medical in 2009. The technology may be used for the treatment of pain, including neuropathic pain, that occurs in diabetes. It embodies a direct production and release of Endomorfin peptides....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics